Regulatory approval for taranabant, an investigational medicine, to treat obesity and is discontinuing its Phase III clinical development program for taranabant for obesity will not be sought. 

Link:http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html

Source:Merck